Find Paid Clinical Trials in Oklahoma

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in Oklahoma

Top of Directory » All Locations » United States » Oklahoma




  • AZD6244 in Treating Patients With Recurrent or Persistent Endometrial Cancer

    Condition:   Endometrial Cancer
    Interventions:   Drug: MEK inhibitor AZD6244;   Other: laboratory biomarker analysis
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Phase IIb 78-week Study in Patients on a Basal Insulin +/- Metformin and/or Sulfonylurea and Are Not at Goal to Add BI 10773 vs. Placebo

    Condition:   Diabetes Mellitus, Type 2
    Intervention:   Drug: BI 10773
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Recruiting - verified November 2009

  • Coagulation Factors, Cytokines and Tissue Injury Markers in Sepsis

    Condition:   Sepsis
    Intervention:  
    Sponsors:   University of Oklahoma;   Oklahoma Medical Research Foundation
    Recruiting - verified November 2009

  • Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease

    Conditions:   Chronic Kidney Disease;   Infection, Bacteria Confirmed;   Infection, Bacteria Suspected
    Intervention:   Drug: Daptomycin
    Sponsors:   University of Oklahoma;   Cubist Pharmaceuticals
    Not yet recruiting - verified November 2009

  • A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Pulmonary Disease, Chronic Obstructive
    Interventions:   Drug: GW642444 Inhalation Powder;   Drug: FF/GW642444 Inhalation Powder
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Study Evaluating the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis

    Condition:   Active Rheumatoid Arthritis
    Intervention:   Drug: SBI-087
    Sponsor:   Wyeth
    Recruiting - verified November 2009

  • A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Traditional Clomiphene Citrate Administration vs. Stair-step Approach

    Conditions:   Ovulatory Dysfunction;   Anovulation;   Ovulation Induction
    Interventions:   Drug: clomiphene citrate;   Drug: clomiphene citrate
    Sponsor:   University of Oklahoma
    Not yet recruiting - verified November 2009

  • The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

    Condition:   Onychomycosis
    Interventions:   Drug: IDP-108;   Drug: Vehicle
    Sponsor:   Dow Pharmaceutical Sciences
    Not yet recruiting - verified November 2009

  • Study of A3309 in Patients With Chronic Idiopathic Constipation

    Conditions:   Constipation;   Chronic Constipation
    Intervention:   Drug: A3309
    Sponsor:   Albireo
    Recruiting - verified November 2009

  • Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

    Conditions:   Arthritis;   Arthritis, Rheumatoid;   Autoimmune Diseases
    Interventions:   Drug: golimumab;   Drug: golimumab or placebo;   Drug: golimumab or placebo
    Sponsors:   Centocor, Inc.;   Schering-Plough
    Recruiting - verified November 2009

  • Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding

    Condition:   Gastrointestinal Bleeding
    Interventions:   Drug: tranexamic acid;   Other: Placebo
    Sponsor:   University of Oklahoma
    Not yet recruiting - verified October 2009

  • Investigate the Effect of Different Doses of AZD3355 as add-on to Proton Pump Inhibitor (PPI) in Gastroesophageal Reflux Disease (GERD) Patients With Partial Response to PPI

    Conditions:   Gastroesophageal Reflux Disease;   Acid Reflux;   Heartburn;   Regurgitation
    Interventions:   Drug: AZD3355;   Drug: AZD3355;   Drug: AZD3355;   Drug: AZD3355;   Drug: Placebo
    Sponsor:   AstraZeneca
    Recruiting - verified October 2009

  • Levacor™ Ventricular Assist Device (VAD) Bridge to Transplant Study

    Condition:   Advanced Heart Failure
    Intervention:   Device: Levacor Ventricular Assist Device
    Sponsor:   World Heart Corporation
    Recruiting - verified November 2009

  • Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

    Conditions:   Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy

    Condition:   Pregnancy Prevention
    Intervention:   Drug: DR-103
    Sponsor:   Teva Women's Health
    Recruiting - verified October 2009

  • TAXUS Libertē Post Approval Study

    Condition:   Coronary Artery Disease
    Interventions:   Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent;   Drug: prasugrel;   Drug: placebo;   Drug: aspirin
    Sponsors:   Boston Scientific Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.
    Not yet recruiting - verified November 2009

  • Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

    Condition:   Type II Diabetes Mellitus
    Interventions:   Drug: JTT-654;   Drug: JTT-654 Placebo
    Sponsor:   Akros Pharma Inc.
    Recruiting - verified November 2009

  • Safety and Tolerability of TAK-491 Plus Chlorthalidone Compared to Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Essential Hypertension

    Condition:   Essential Hypertension
    Interventions:   Drug: TAK-491 and chlorthalidone;   Drug: Olmesartan medoxomil-hydrochlorothiazide
    Sponsor:   Takeda Global Research & Development Center, Inc.
    Recruiting - verified November 2009

  • The Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis to Assess the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

    Condition:   Rheumatoid Arthritis
    Interventions:   Biological: Placebo;   Biological: Certolizumab pegol
    Sponsor:   UCB, Inc.
    Recruiting - verified November 2009

  • Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

    Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
    Interventions:   Biological: bevacizumab;   Drug: ABT-888;   Drug: carboplatin;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study of Tocilizumab in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis

    Condition:   Juvenile Idiopathic Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: tocilizumab;   Drug: placebo;   Drug: NSAIDs, corticosteroids, methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout

    Condition:   Gout
    Interventions:   Drug: placebo;   Drug: BCX4208
    Sponsor:   BioCryst Pharmaceuticals
    Recruiting - verified November 2009

  • Dapagliflozin DPPIV Inhibitor add-on Study

    Condition:   Type 2 Diabetes
    Interventions:   Drug: Dapagliflozin;   Drug: Placebo
    Sponsors:   AstraZeneca;   Bristol-Myers Squibb
    Recruiting - verified November 2009

  • Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725

    Condition:   Congenital FXIII Deficiency
    Intervention:   Drug: recombinant factor XIII
    Sponsor:   Novo Nordisk
    Recruiting - verified October 2009

  • Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

    Condition:   Endometrial Cancer
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: temsirolimus
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: insulin glargine + preprandial lispro insulin;   Biological: albiglutide + insulin glargine
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Clinical Study to Test a New Drug to Treat Major Depression

    Condition:   Major Depressive Disorder (MDD)
    Interventions:   Drug: GW856653;   Other: Placebo;   Drug: GW856653
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Efficacy and Safety Study of NBI-56418 Na in Subjects With Endometriosis

    Conditions:   Endometriosis;   Pain
    Interventions:   Drug: NBI-56418;   Drug: Placebo
    Sponsor:   Neurocrine Biosciences
    Recruiting - verified November 2009

  • A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

    Conditions:   Low Back Pain;   Low Back Pain, Recurrent
    Interventions:   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: Placebo
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified November 2009

  • A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

    Conditions:   Osteoarthritis;   Osteoarthritis, Hip;   Osteoarthritis, Knee;   Pain;   Arthralgia;   Joint Pain
    Interventions:   Drug: JNJ-42160443;   Drug: Placebo;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified November 2009

  • Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone

    Condition:   Diabetes Mellitus, Type II
    Interventions:   Drug: Placebo;   Drug: Dutogliptin
    Sponsors:   Forest Laboratories;   Phenomix
    Recruiting - verified November 2009

  • CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: JNJ-28431754;   Drug: glimepiride
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified November 2009

  • A Study in Patients With Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Biological: LY2439821;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

    Condition:   Attention Deficit Hyperactivity Disorder
    Intervention:   Drug: LY2216684
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • A Study for Adult Patients With Fibromyalgia

    Conditions:   Fibromyalgia, Primary;   Fibromyalgia, Secondary
    Interventions:   Drug: Duloxetine;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

    Condition:   Systemic Lupus Erythematosus
    Interventions:   Drug: placebo;   Drug: rontalizumab
    Sponsor:   Genentech
    Recruiting - verified November 2009

  • A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant (MK0524A)) in Patients With Dyslipidemia

    Condition:   Dyslipidemia
    Interventions:   Drug: ER niacin (+) laropiprant (ERN/LRPT);   Drug: Comparator: ER niacin (+) laropiprant (ERN/LRPT);   Drug: Comparator: Extended-release niacin (ERN);   Drug: Comparator: Placebo to ERN/LRPT
    Sponsor:   Merck
    Recruiting - verified October 2009

  • Study of Blood Samples From Newborns With Down Syndrome

    Condition:   Leukemia
    Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine Carcinosarcoma

    Condition:   Sarcoma
    Interventions:   Drug: carboplatin;   Drug: ifosfamide;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of VX-770 in Cystic Fibrosis Subjects Age 12 and Older Homozygous for the F508del-CFTR Mutation

    Condition:   Cystic Fibrosis
    Interventions:   Drug: VX-770;   Drug: Placebo
    Sponsors:   Vertex Pharmaceuticals Incorporated;   Cystic Fibrosis Foundation
    Recruiting - verified November 2009

  • Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II or Stage III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

    Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study of the Safety and Efficacy of JNJ-39758979 in the Treatment of Adults With Asthma

    Condition:   Asthma
    Intervention:   Drug: JNJ39758979
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified November 2009

  • Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin

    Condition:   Diabetes Mellitus, Type II
    Interventions:   Drug: Dutogliptin;   Drug: Placebo
    Sponsors:   Forest Laboratories;   Phenomix
    Recruiting - verified October 2009

  • Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

    Conditions:   Kidney Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of ITCA 650 in Subjects With Type 2 Diabetes Mellitus

    Condition:   Type 2 Diabetes
    Interventions:   Drug: ITCA 650;   Drug: Exenatide
    Sponsor:   Intarcia Therapeutics
    Recruiting - verified November 2009

  • Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage III or Stage IVA Endometrial Cancer

    Condition:   Endometrial Cancer
    Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

    Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
    Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Subjects With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

    Conditions:   Primary Hypercholesterolemia;   Mixed Hyperlipidemia
    Interventions:   Drug: SCH 900271;   Drug: SCH 900271;   Drug: SCH 900271;   Drug: SCH 900271;   Drug: SCH 900271;   Drug: Placebo
    Sponsor:   Schering-Plough
    Recruiting - verified October 2009

    • Menu
    Find Paid Clinical Trials